Substituted hydroxyethylamine aspartyl protease inhibitors

Details Substituted hydroxyethylamine aspartyl protease inhibitors Substituted hydroxyethylamine aspartyl protease inhibitors

2009-03-03

2010-12-28

Solola, Taofiq A (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S362000, C546S159000, C548S128000

Reexamination Certificate

active

07858642

ABSTRACT:
The invention relates to novel compounds and also to methods of treating at least one disease, disorder, or condition associated with amyloidosis using such compounds. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.

REFERENCES:
patent: 4522811 (1985-06-01), Eppstein et al.
patent: 5095006 (1992-03-01), Bender et al.
patent: 5132400 (1992-07-01), Gammill et al.
patent: 5145684 (1992-09-01), Liversidge et al.
patent: 5254595 (1993-10-01), Guzzi et al.
patent: 5362912 (1994-11-01), Sowin et al.
patent: 5387742 (1995-02-01), Cordell
patent: 5441870 (1995-08-01), Seubert et al.
patent: 5593846 (1997-01-01), Schenk et al.
patent: 5604102 (1997-02-01), McConlogue et al.
patent: 5612486 (1997-03-01), McConlogue et al.
patent: 5696270 (1997-12-01), Kempf et al.
patent: 5720936 (1998-02-01), Wadsworth et al.
patent: 5721130 (1998-02-01), Seubert et al.
patent: 5744346 (1998-04-01), Chrysler et al.
patent: 5766846 (1998-06-01), Schlossmacher et al.
patent: 5811633 (1998-09-01), Wadsworth et al.
patent: 5850003 (1998-12-01), McLonlogue et al.
patent: 5877015 (1999-03-01), Hardy et al.
patent: 5877399 (1999-03-01), Hsiao et al.
patent: 5892052 (1999-04-01), Kempf et al.
patent: 5912410 (1999-06-01), Cordell
patent: 5942400 (1999-08-01), Anderson et al.
patent: 6045829 (2000-04-01), Liversidge et al.
patent: 6150530 (2000-11-01), Kempf et al.
patent: 6191166 (2001-02-01), Audia et al.
patent: 6379666 (2002-04-01), Tobinick
patent: 7109217 (2006-09-01), Coburn et al.
patent: 2002/0019403 (2002-02-01), Hom et al.
patent: 2003/0096864 (2003-05-01), Fang et al.
patent: 2004/0044072 (2004-03-01), Tenbrink et al.
patent: 2005/0043290 (2005-02-01), Cumming et al.
patent: 2005/0119227 (2005-06-01), Cumming et al.
patent: 2006/0014737 (2006-01-01), John et al.
patent: 2007/0225372 (2007-09-01), Bueno Melendo et al.
patent: 0 279 707 (1988-08-01), None
patent: 0 375 560 (1990-06-01), None
patent: WO 98/22597 (1998-05-01), None
patent: WO 99/64001 (1999-12-01), None
patent: WO 00/17369 (2000-03-01), None
patent: WO 00/47618 (2000-08-01), None
patent: WO 01/10387 (2001-02-01), None
patent: WO 01/23533 (2001-04-01), None
patent: WO 02/02512 (2002-01-01), None
patent: WO 02/05804 (2002-01-01), None
patent: WO 02/09760 (2002-02-01), None
patent: WO 02/085877 (2002-10-01), None
patent: WO 02/098849 (2002-12-01), None
patent: WO 02/100399 (2002-12-01), None
patent: WO 02/100820 (2002-12-01), None
patent: WO 03/002122 (2003-01-01), None
patent: WO 03/006021 (2003-01-01), None
patent: WO 03/006423 (2003-01-01), None
patent: WO 03/029169 (2003-04-01), None
patent: WO 03/040096 (2003-05-01), None
patent: WO 03/050073 (2003-06-01), None
patent: WO 03/072535 (2003-09-01), None
patent: WO 2004/024081 (2004-03-01), None
patent: WO 2004/029019 (2004-04-01), None
patent: WO 2004/043916 (2004-05-01), None
patent: WO 2004/050609 (2004-06-01), None
patent: WO 2004/050619 (2004-06-01), None
patent: WO 2004/069793 (2004-08-01), None
patent: WO 2004/094384 (2004-11-01), None
patent: WO 2004/094413 (2004-11-01), None
patent: WO 2005/014517 (2005-02-01), None
patent: WO 2005/014540 (2005-02-01), None
patent: WO 2005/016876 (2005-02-01), None
patent: WO 2005/058915 (2005-06-01), None
patent: WO 2005/087714 (2005-09-01), None
patent: WO 2005/108358 (2005-11-01), None
patent: WO 2005/108391 (2005-11-01), None
Ajay, et al., “Designing libraries with CNS activity,” J. Med. Chem., (1999) 42, 4942-4951.
Albright, J.D., “Synthesis of 1,4,5,6,-Tetrahydropyrazolo[3,4-d]pyrido[3,2-b]azepine,” J. Heterocycl. Chem., (2000), 37, 41-46.
Alexakis et al., “A practical, solvent free, one-pot synthesis of C2-symmetrical secondary amines,” Tet. Lett. 2004, 45: 1449-1451.
Alvarez, A., et al., “Synthesis of 3-Arylpyrroles and 3-Pyrrolylacetylenes by Palladium-Catalyzed Coupling Reactions”, J. Org. Chem., (1992), 57, 1653-1656.
Anderson, G.W., et al., “Studies in Chemotherapy. X. Antithyroid Compounds. Synthesis of 5- and 6- Substituted 2-Thiouracils from b-Oxoesters and Thiourea,” J. Am. Chem. Soc., (1945), 67, 2197-2200.
Anzalone, L. and Hirsch, J.A., “Substituent Effects on Hydrogenation of Aromatic Rings: Hydrogenation vs. Hydrogenolysis in Cyclic Analogues of Benzyl Ethers,” J. Org. Chem., (1985), 50, 2128-2133.
Beam, C.F., et al., “Preparation of Pyrazoles from the C(α)NN-Trianion of Hyrdrazones having an α-Hydrogen Atom,” J. Chem. Soc., Section C: Organic (1971), 9, 1658-1660.
Becker, D.P. & Flynn, D.L., “A Short Synthesis of 1-Azaadamantan-4-one and the 4r and 4s Isomers of 4-Amino-l-azaadamantane,” Synthesis, (1992), 1080-1082.
Benedetti, et al., “Versatile and Stereoselective Synthesis of Diamino Diol Dipeptide Isosteres, Core Units of Psuedopeptide HIV Protease Inhibitors,” J. Org. Chem., (1997), 62, 9348-9353.
Boeckman, R. K., Jr.; Liu, X., “Controllable Monoaddition of Carbon Nucleophiles to 1,2,3,4-Diepoxybutane: Two-directional Chain Extension of a C2 Symmetric Four Carbon Diepoxide as a Route to Differentiated Syn 1,2-Diols,” Synthesis, (2002), 14, 2138-2142.
Castro, B., et al., “Reactifs de Couplage Peptidique IV (1)—L'Hexaflourophosphate De Benzotriazolyl N-Oxytrisdimethylamino Phosphonium (B.O.P.),” Tet. Letters, (1975), 14, 1219-1222.
Cerri, A., et al., “17beta-O-Aminoalkyloximes of 5beta-androstane-3beta,14beta-diol with digitalis-like activity: synthesis, cardiotonic activity, structure-activity relationships, and molecular modeling of the Na(+),K(+)-ATPase receptor.,” J. Med. Chem.; 2000, 43, 2332-2349.
Citron, et al., “Mutation of the B-amyloid precursor protein in familial Alzheimer's disease increases B-protein production,” Nature, (1992), 360:672-674.
Copending U.S. Appl. No. 11/038,790, filed Jan. 21, 2005, published Jan. 19, 2006.
U.S. Appl. No. 11/074,828, filed Mar. 9, 2005, published Oct. 27, 2005.
U.S. Appl. No. 11/075,292, filed Mar. 9, 2005, published Nov. 24, 2005.
Copending U.S. Appl. No. 11/075,294, filed Mar. 9, 2005, published Oct. 27, 2005.
Copending U.S. Appl. No. 11/075,445, filed Mar. 9, 2005, published Jan. 19, 2006.
U.S. Appl. No. 11/177,324, filed Jul. 11, 2005, published Jun. 22, 2006, issued as U.S. Patent No. 7,385,085.
Copending U.S. Appl. No. 11/177,348, filed Jul. 11, 2005, published Jun. 15, 2006.
Copending U.S. Appl. No. 11/211,484, filed Aug. 26, 2005, published Apr. 6, 2006.
Copending U.S. Appl. No. 11/546,347, filed Oct. 12, 2006, published Jun. 28, 2007.
Copending U.S. Appl. No. 11/659,788, filed Aug. 21, 2007, published Jul. 10, 2008.
Copending U.S. Appl. No. 12/117,094, filed May 8, 2008, published Feb. 12, 2009.
Coria F. and Rubio, I., “Cerebral amyloid angiopathies,” Neuropath Appl. Neurobiol., (1996) 22, 216-227.
Cornelius, L.A.M.; Combs, D.W., “A Convenient Synthesis of Mono- and Polyhalogenated Benzocyclanones,” Synthetic Communications, (1994), 24, 2777-2788.
Dai, C. and Fu, G.J., “The first general method for palladium-catalyzed Negishi cross-coupling of aryl and vinyl chlorides: use of commercially available Pd(P(t-Bu)(3))(2) as a catalyst,” J. Am. Chem. Soc., (2001), 123, 2719-2724.
Dantzig, A.H., et al., “Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979,” Cancer Research, (1996), 56, 4171-4179.
Dovey, et al., “Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain,” J. Neurochemistry, (2001), 76:173-181.
Emilien, G., et al., “Prospects for Pharmacological Intervention in Alzheimer Disease,” Arch. Neurol. (2000), 57:454-459.
Ertl, P., et al., “Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties,” J. Med. Chem., (2000), 43:3714-3717.
Fujita, T., et al., “A new substituent constant, pie-derived from

Affiliated with

Also associated with

Rating

Substituted hydroxyethylamine aspartyl protease inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted hydroxyethylamine aspartyl protease inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted hydroxyethylamine aspartyl protease inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4184440